Literature DB >> 17263710

Prescription patterns in patients with systolic heart failure at hospital discharge: why beta blockers are underprescribed or prescribed at low dose in real life?

M B Yilmaz1, M Refiker, Y Guray, U Guray, H Altay, B Demirkan, V Caldir, S Korkmaz.   

Abstract

Systolic heart failure (SHF) is associated with increased morbidity and mortality. Beta-blockers (BB) were shown to provide mortality benefit in patients with SHF, and currently indicated in all stages of patients with SHF. We evaluated the factors influencing the prescription of BBs at discharge in patients hospitalised with HF. Hospital discharge records of consecutive 1418 patients (996 men, 422 women) with a mean age of 57 +/- 15 years, hospitalised and treated for SHF (EF < 45%), were retrospectively reviewed. Mean age of female (n = 422) and male patients (n = 996) was similar (58 +/- 15 years vs. 58 +/- 14 years, p = 0.654). Mean EF was 33 +/- 7%, and not different for each sex (p = 0.288). BBs were present in 47.4% of patients at hospital discharge, and female patients were more frequently prescribed than men (51.7% vs. 45.7%, p = 0.036). Patients who were prescribed BBs at discharge were younger than those who were not (p = 0.034). Patients who were prescribed BBs at discharge had significantly higher EF than those who were not (p = 0.019). Older patients were prescribed low-dose BBs. Besides, creatinine level was significantly higher in the group who were prescribed low-dose BBs than those who were prescribed high dose. However, EF was significantly lower in the group, who were prescribed low-dose BBs than in those prescribed moderate-high dose (33 +/- 7% vs. 35 +/- 7%, p = 0.023). There exist several factors associated with underuse of this highly recommended medication in patients with HF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17263710     DOI: 10.1111/j.1742-1241.2006.01157.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  4 in total

Review 1.  Managing beta-blockers in acute heart failure: when to start and when to stop?

Authors:  Mehmet Birhan Yilmaz; Said Laribi; Alexandre Mebazaa
Journal:  Curr Heart Fail Rep       Date:  2010-09

2.  Acute heart failure with accompanying chronic obstructive pulmonary disease: should we focus on beta blockers?

Authors:  M R Ege; U Guray; Y Guray; M B Yilmaz; O Yucel; A Zorlu; I Tandogan
Journal:  Herz       Date:  2012-06-16       Impact factor: 1.443

3.  Prescription Practices in Patients With Mild to Moderate CKD in India.

Authors:  Narayan Prasad; Ashok Kumar Yadav; Monica Kundu; Jasmin Sethi; Ajay Jaryal; Dipankar Sircar; Gopesh K Modi; Kajal Kamboj; Manisha Sahay; Natarajan Gopalakrishnan; Prabhjot Kaur; Sanjay Vikrant; Santosh Varughese; Seema Baid-Agrawal; Shivendra Singh; Sishir Gang; Sreejith Parameswaran; Vivek Kumar; Arpita Ghosh; Vivekanand Jha
Journal:  Kidney Int Rep       Date:  2021-06-26

4.  Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.

Authors:  Bryan Wai; Leighton G Kearney; David L Hare; Michelle Ord; Louise M Burrell; Piyush M Srivastava
Journal:  Cardiovasc Diabetol       Date:  2012-02-14       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.